Clinical trials: Diabetes Type I
Type 1 or Type 2 Diabetes
Bigfoot Unity Real World Study
This study is observational, designed to collect real world use and safety data for those using the Bigfoot Unity Diabetes Management System for 12 months.
- Trial name
- BURST (NCT05088265)
- Testing
- Bigfoot Unity Diabetes Management System
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Bigfoot Biomedical Inc.
Type 1 Diabetes
A Study of Autologous Induced Islet Body With Type 1 Diabetes
This is a single centre、single arm、open-label study，to investigate the safety and efficacy of Autologous induced islet body With Type 1 diabetes
- Trial name
- NCT03728296
- Testing
- islet body
- Volunteers
- 20 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Type 1 Diabetes Mellitus
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients…
- Trial name
- NCT00920582
- Testing
- Teplizumab Herold Regimen, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen
- Where
- 118 sites in United States, Belgium and 14 more
- Volunteers
- 254 people
- Sponsor
- MacroGenics
Type 1 Diabetes Mellitus
Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes
This is a double-blind, randomized , placebo-controlled study to evaluate the safety and tolerability of AVT001, and to assess AVT001 as a potential treatment for type 1 diabetes (T1D).
- Trial name
- NCT03895996
- Testing
- AVT001
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Avotres Inc.
Type 2 Diabetes
To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin
The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes on top of insulin.
- Trial name
- NCT00768105
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
The objective of the current study is to determine the relative bioavailability of a BI 10773 / metformin fixed dose combination tablet compared to single tablets of BI 10773 and metformin when administered together and to assess…
- Trial name
- NCT01211197
- Testing
- C: BI 10773 / metformin tablet, B: BI 10773 tablet and metformin tablet, A: BI 10773 / metformin tablet
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients
The purpose of this study is to determine whether AZD1656 will affect the Pharmacokinetics and Pharmacodynamics of Warfarin in T2DM patients.
- Trial name
- NCT01103609
- Testing
- Warfarin, AZD1656
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Type 1 Diabetes, Type 2 Diabetes
Closed Loop Glucose Control in a Simulated ICU Setting
This is a proof of concept safety study of a rule-based closed loop glucose control system designed for use in the intensive care unit setting.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Stress Induced Hyperglycemia
- Trial name
- NCT07646067
- Testing
- FUSION closed loop glucose control system
- Volunteers
- 6 people
- Sponsor
- Ideal Medical Technologies
Diabetic Kidney Disease
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due…
- Trial name
- NCT05514548
- Testing
- INV-202
- Where
- 72 sites in United States, Canada and 5 more
- Volunteers
- 265 people
- Sponsor
- Inversago Pharma Inc.
Diabetes Mellitus, Type 1
Effect of Fiasp® in Type 1 Diabetes Treatment
Fiasp® is a meal-time insulin that has been available in Sweden since June 2017. This study will investigate the effectiveness of Fiasp® in treating Type 1 Diabetes Mellitus.
- Trial name
- NCT03895515
- Testing
- Fiasp®
- Where
- Sweden
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)
This trial is conducted in Europe, Asia and South America. A one-year clinical trial to compare the safety of inhaled human insulin to subcutaneous insulin aspart in subjects with type 1 or type 2 diabetes and chronic obstructive…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Chronic Obstructive Pulmonary Disease
- Trial name
- iINHALE 8 (NCT00472953)
- Testing
- inhaled human insulin, insulin aspart
- Where
- 27 sites in Argentina, India and 5 more
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Healthy, Type 1 Diabetes
Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Autoimmune diseases happen when the immune system does not identify part of the body as belonging to it.
- Trial name
- NCT00896077
- Testing
- Lisofylline
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- DiaKine Therapeutics, Inc.
Type 1 Diabetes
A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus
VC01-103 will evaluate an experimental combination product, cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes.
- Trial name
- VC01-103 (NCT04678557)
- Testing
- VC-01 Combination Product
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- ViaCyte
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Evaluation of the Bioavailability of Pramlintide
This is a randomized, open-label, crossover study to examine the bioavailability of pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus using insulin.
- Trial name
- NCT00042471
- Testing
- Pramlintide acetate
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research
Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus
Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
This is a randomized, open-label, active-controlled, single-dose, 3-treatment, 3-period, 3-way crossover, comparative PD and PK inpatient study in adults with T1D.
- Trial name
- NCT04074317
- Testing
- PRAM9, Regular Insulin + Pramlintide, Regular Insulin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Xeris Pharmaceuticals
Diabetes Mellitus, Type 2
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of CNTO 3649 following a single dose in healthy adults and following multiple doses in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT00882726
- Testing
- CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients)
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Type 1 Diabetes Mellitus
The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
This randomized, single-blind, 3 arm, parallel group, placebo controlled PK/PD study will enrol 30 Japanese male and female patients with T1DM and age 18 to 65 years, with inadequate glycemic control on insulin defined as HbA1c ≥…
- Trial name
- NCT02582840
- Testing
- Dapagliflozin 5mg, Dapagliflozin 10mg
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Hypoglycemia, Diabetes Mellitus, Type 1
A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
The objective of the trial is to demonstrate superiority of dasiglucagon compared to placebo following a single subcutaneous dose administered to subjects with type 1 diabetes mellitus (T1DM) with insulin-induced hypoglycemia.
- Trial name
- NCT03378635
- Testing
- Dasiglucagon, GlucaGen
- Where
- 5 sites in United States, Austria and 2 more
- Volunteers
- 170 people
- Sponsor
- Zealand Pharma
Type 1 Diabetes Mellitus
TAK-329 Glucose Clamp Study
The purpose of this study is to compare the safety, tolerability, pharmacokinetic and pharmacodynamic properties of single doses of TAK-329 with a single dose of a subcutaneously-injected rapid-acting insulin analog in…
- Trial name
- NCT01311076
- Testing
- TAK-329, Insulin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.